卵巢癌是女性生殖器官常見的惡性腫瘤之一, 其死亡率居?jì)D科惡性腫瘤首位, 且發(fā)病率逐年增加。全球新批準(zhǔn)并上市的治療卵巢癌的藥物有貝伐單抗、曲貝替定、人參皂苷以及一些新制劑, 處于研發(fā)后期的抗卵巢癌藥物有奧拉帕尼、西地尼布、nintedanib、trebananib以及一些抗卵巢癌藥的新劑型品種等。對近年來上市和處于研發(fā)后期的卵巢癌的治療藥物進(jìn)行了詳細(xì)介紹, 同時(shí)對抗卵巢癌藥的未來發(fā)展方向進(jìn)行了展望, 以期為抗卵巢癌藥物的研發(fā)提供參考。

Ovarian cancer is one of the most common gynecological malignant tumors in women, and its mortality heads the list. The incidence rate has increased year by year. Drugs in treatment of ovarian cancer approved for sale include bevacizumab, trabectedin, ginsenoside, and some new formulations; Ovarian cancer drugs under development include olaparib, cediranib, nintedanib, trebananib, and some new formulations. Ovarian cancer drugs (launched and R & D) are introduced, and the future development direction of ovarian cancer drugs is prospected in this paper, in order to provide a basis for ovarian cancer drugs.